Company: IONQ
Filing Date: 2025-06-09
Form Type: 8-K
Source: 0001193125-25-137398
Chunk: 0

Company: IonQ, Inc.
Filing Date: 2025-06-09
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

On June 7, 2025, IonQ, Inc., a Delaware corporation (the “ Company”), Oxford Ionics Limited, a private limited company incorporated in England and Wales (“ Oxford Ionics”), the Sellers (as defined in the Agreement) and Oxford Science Enterprises plc, solely in its capacity as the representative of the Sellers, entered into a Share Purchase Agreement (the “ Agreement”) pursuant to which the Company has agreed to acquire all of the issued and outstanding shares of Oxford Ionics (the “ Transaction”).

Pursuant to the terms of the Agreement and subject to the satisfaction or waiver of certain conditions set forth in the Agreement, the aggregate consideration payable by the Company to the Sellers at the closing (the “ Closing”) of the Transaction (the “ Transaction Consideration”) shall consist of (1) a number of the Company’s common stock, par value $0.0001 per share (“ Common Stock”) with a value of $1,065,000,000, subject to adjustment as described in the Agreement, plus (2) $10,000,000 in cash. The Transaction Consideration will be reduced by any leakage (other than customary permitted leakage exceptions) incurred by Oxford Ionics since April 30, 2025, as further described in the Agreement. The number of shares of Common Stock to be issued will not be less than 21,143,538 or more than 35,241,561. The final number of shares of Common Stock to be issued as Transaction Consideration will be calculated using the volume-weighted average price for shares of Common Stock for the 20 trading days immediately preceding, but not including, the third business day prior to the date of the Closing, but will not be more than $50.37 per share or less than $30.22 per share.

Under the Agreement, Dr. Chris Ballance and Dr. Thomas Harty (the “ Founders”) will be subject to a lock-upwith respect to a portion of the Common Stock received as Transaction Consideration, pursuant to which, subject to certain exceptions, the Founders may not sell or otherwise transfer the Common Stock they receive as Transaction Consideration, with each Founder agreeing not to transfer (i) more than 40% of the Common Stock received by such Founder at Closing prior to the one-yearanniversary of the Closing; (ii) more than 52% of the Common Stock received by such Founder at Closing prior to the two